

**Ravi A. Madan, M.D.**

**Senior Clinician**

**Clinical Director**

Genitourinary Malignancies Branch

Center for Cancer Research,

National Cancer Institute, NIH

Bethesda, MD

**Program Director**

Physician Early Scientist Investigator Program

Center for Cancer Research,

National Cancer Institute, NIH

Bethesda, MD

Building 10, 13N240b

10 Center Drive

Bethesda, M

(301) 222-7762

madanr@mail.nih.gov

**Positions and Training**

<b>Senior Clinician</b>	<b>Genitourinary Malignancies Branch</b> Center for Cancer Research, National Cancer Institute, NIH Bethesda, MD	12/18-present
<b>Clinical Director</b>	<b>Genitourinary Malignancies Branch</b> Center for Cancer Research, National Cancer Institute, NIH Bethesda, MD	1/14-present
<b>Staff Clinician</b>	<b>Genitourinary Malignancies Branch</b> Center for Cancer Research, National Cancer Institute, NIH Bethesda, MD	1/14-12/18
<b>Attending Oncologist</b>	<b>Walter Reed National Military Medical Center</b> Genitourinary Oncology Clinic Bethesda, MD	7/09-present
<b>Assistant Clinical Investigator</b>	<b>National Cancer Institute, NIH</b> Laboratory of Tumor Immunology and Biology & Medical Oncology Branch Bethesda, MD	7/09-12/13
<b>Postgraduate Training</b>	<b>National Cancer Institute, NIH</b> Bethesda, MD Oncology/Hematology Fellowship	7/05-6/09
	<b>East Orange VA Hospital</b> East Orange, NJ UMDNJ – University Hospital Internal Medicine Program Chief Medical Resident	7/04-6/05
	<b>UMDNJ – University Hospital</b> Newark, NJ Internal Medicine Residency Program	7/01-6/04
<b>Education</b>	<b>UMDNJ – New Jersey Medical School</b> Newark, NJ Doctor of Medicine	8/97-5/01
	<b>University of Michigan</b> Ann Arbor, MI B.S. in Biology and Economics	9/93-5/97

**NIH and National Service Positions**

Ad-Hoc Reviewer, Department of Veterans Affairs (VA) Cooperative Studies Scientific Evaluation Committee (CSSEC)	7/1/21
Ad-Hoc Member, Oncologic Drugs Advisory Committee (FDA) – Review of Checkpoint Inhibitors in Bladder Cancer	4/28/21

Chair, Veteran's Administration Precision Oncology Special Interest Panel.	2020-2021
Chair, Veteran's Administration Review Committee for Emergent COVID19 Studies	4-6/2020
National Cancer Institute Clinical Review Panel	2020-
Organizing Committee: NIH-AACR Cancer Autoimmunity Immunotherapy Meeting	2019-
Meeting Co-Chair: ASCO-SITC Pre-Annual Seminar on Immunotherapy	2019
Organizing Committee: ASCO-SITC Pre-Annual Seminar on Immunotherapy	2017-2018
Program Director: Physician Scientist Early Investigator Program, Center for Cancer Research, NCI (formerly Clinical Investigator Development Program).	6/2018-
Chair: 2018 ASCO Scientific Program Committee	2018
ASCO Scientific Program Committee for Annual Meeting	2016-2018
SITC Cancer Immunotherapy Guidelines Prostate Subcommittee	2016-present
Consultant to the Oncologic Drugs Advisory Committee (FDA)	2016-present
ASCO Annual Meeting Auditor	2016-2019
Reviewer: ASCO Annual Meeting Education Book	2015-2016
Grant Reviewer: NCI Cancer Clinical Investigator Team Leadership Award	5/2014
Medical Oncology Fellowship Core Curriculum Committee	9/11-present
NCI Center for Cancer Research Scientific Review Committee	2014-2016
Medical Oncology Branch/ CCR Scientific Review Committee	7/09-2016
Guest Expert Panelist: Medicare Advisory Committee Meeting on Activated Cellular Therapy in Prostate Cancer	11/2010
<b><u>Editor and Expert Reviewer</u></b>	
Grant Reviewer: UCSF Benioff Initiative for Prostate Cancer Research	2019
Grant Reviewer: 2019 Prostate Cancer Research Program (PCRP) for the Department of Defense Congressionally Directed Medical Research Programs	2019
Grant Reviewer: German Federal Ministry of Education and Research	2019
Associate Editor, Clinical/Translational Oncology, <i>Journal of ImmunoTherapy of Cancer</i>	2018-present
Section Editor, Immuno-Oncology, <i>The Oncologist</i>	2018-present
Grant Reviewer: Swiss National Science Foundation	2018
Member, European Academy for Tumor Immunology	2016
Grant Reviewer: Dutch Cancer Society (KWF)	2016

Grant Reviewer: Cancer Research Wales (Velindre Cancer Centre, Cardiff, UK)	2015
Grant Reviewer: Prostate Cancer Foundation (Challenge Awards)	7/2012
Grant Reviewer: Prostate Action (United Kingdom)	2012, 2013 2016
Grant Reviewer: Department of Veterans Affairs Cooperative Studies Program (CSP)	1/2011
Grant Reviewer: Department of Veterans Affairs Merit Review Subcommittee for the Oncology (ONC A) Program	12/10-present

**Clinical Research Activity**

**Principal Investigator:** Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer (NCT0463352)

**Principal Investigator:** Radium-223 in Biochemically Recurrent Prostate Cancer (NCT04206319)

**Principal Investigator:** Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (NCT03531827)

**Principal Investigator:** Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (NCT03315871)

**Principal Investigator:** Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer (NCT03072160)

**Principal Investigator:** Docetaxel and Prostavac in Metastatic Castration Sensitive Prostate Cancer (NCT02649855)

**Principal Investigator:** Prostavac in Biochemically Recurrent Prostate Cancer (NCT02649439)

**Principal Investigator:** A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (NCT02616185) - site PI

**Principal Investigator:** A Randomized Phase II Study of L-BLP25 in Combination with Standard Androgen-Deprivation Therapy and Radiation Therapy for Newly Diagnosed, High-Risk Prostate Cancer Patients L-BLP25 in Prostate Cancer (NCT01496131)

**Principal Investigator:** A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer (NCT01867333)

**Principal Investigator:** A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-metastatic Castration Sensitive Prostate Cancer (NCT01875250)

**Principal Investigator:** Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide (NCT02130700)

**Principal Investigator:** A Pilot study of recombinant yeast CEA vaccine in patients with recurrent medullary thyroid cancer (NCT01856920)

**Principal Investigator:** A Targeted Phase I/II trial of ZD6474 (Vandetanib CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade®), in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (NCT00923247)

**Principal Investigator:** A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma (NCT00923130)

**Principal Investigator:** A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide vs Flutamide Alone in Patients with Androgen-Insensitive, Nonmetastatic (D0.5) Prostate Cancer (NCT00450463)

**Principal Investigator:** An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant *Saccharomyces cerevisiae* (Yeast) Genetically Modified to Express CEA Protein in Adults with Metastatic CEA-Expressing Carcinoma (NCT00924092)

**Principal Investigator:** A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer (NCT00942578)

**Principal Investigator:** A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients with Androgen-Independent Prostate Cancer (NCT00942578)

Associate Investigator on more than 30 additional trials.

### Publications

1. Wilkinson S, Ye H, Karzai F, Harmon SA, Terrigino NT, VanderWeele DJ, Bright JR, Atway R, Trostel SY, Carrabba NV, Whitlock NC, Walker SM, Lis RT, Abdul Sater H, Capaldo BJ, **Madan RA**, Gulley JL, Chun G, Merino MJ, Pinto PA, Salles DC, Kaur HB, Lotan TL, Venzon DJ, Choyke PL, Turkbey B, Dahut WL, Sowalsky AG. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. *Eur Urol* 2021.
2. **Madan RA**, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. *BJU Int* 2021;127:435-44.
3. **Madan RA**, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner, II, Singh H, Arlen PM, Theoret MR, Marte JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. *J Immunother Cancer* 2021;9.
4. Lochrin SE, Turkbey B, Gasmi B, Schmidt K, Strobe JD, Chau CH, Sissung TM, Price DK, Cordes L, Markolovic S, Wood BJ, Pinto PA, McKinney YL, Shih JH, Levy E, **Madan R**, Dahut W, Choyke PL, Merino M, Figg WD. Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. *Sci Rep* 2021;11:5662.
5. Lee RJ, **Madan RA**, Kim J, Posadas EM, Yu EY. Disparities in Cancer Care and the Asian American Population. *Oncologist* 2021;26:453-60.
6. Karzai F, Walker SM, Wilkinson S, **Madan RA**, Shih JH, Merino MJ, Harmon SA, VanderWeele DJ, Cordes LM, Carrabba NV, Bright JR, Terrigino NT, Chun G, Bilusic M, Couvillon A, Hankin A, Williams MN, Lis RT, Ye H, Choyke PL, Gulley JL, Sowalsky AG, Turkbey B, Pinto PA, Dahut WL. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. *Clin Cancer Res* 2021;27:429-37.
7. Gubbi S, Cordes LM, Klubo-Gwiezdzinska J, **Madan RA**, Nieman LK, Gulley JL, Del Rivero J. In Reply. *Oncologist* 2021;26:e192-e3.

8. DeMaria PJ, Bilusic M, Park DM, Heery CR, Donahue RN, **Madan RA**, Bagheri MH, Strauss J, Shen V, Marte JL, Steinberg SM, Schlom J, Gilbert MR, Gulley JL. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. *Oncologist* 2021;26:e847-e58.
9. Chau V, **Madan RA**, Bilusic M, Owens H, Cordes LM, Marte JL, Gulley JL, Lee JM, Dahut WL, Karzai F. Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. *Clin Genitourin Cancer* 2021.
10. Chau V, **Madan RA**, Aragon-Ching JB. Protein kinase inhibitors for the treatment of prostate cancer. *Expert Opin Pharmacother* 2021;1-11.
11. Bilusic M, McMahon S, **Madan RA**, Karzai F, Tsai YT, Donahue RN, Palena C, Jochems C, Marte JL, Floudas C, Strauss J, Redman J, Abdul Sater H, Rabizadeh S, Soon-Shiong P, Schlom J, Gulley JL. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). *J Immunother Cancer* 2021;9.
12. Wilkinson S, Harmon SA, Terrigino NT, Karzai F, Pinto PA, **Madan RA**, VanderWeele DJ, Lake R, Atway R, Bright JR, Carrabba NV, Trostel SY, Lis RT, Chun G, Gulley JL, Merino MJ, Choyke PL, Ye H, Dahut WL, Turkbey B, Sowalsky AG. A case report of multiple primary prostate tumors with differential drug sensitivity. *Nat Commun* 2020;11:837.
13. Turkbey B, Czarniecki M, Shih JH, Harmon SA, Agarwal PK, Apolo AB, Citrin DE, Gulley JL, Harisinghani M, **Madan RA**, Metwalli AR, Paquette E, Pinto PA, Rais-Bahrami S, Rowe LS, Wood BJ, Jacobs PM, Lindenberg L, Dahut W, Choyke PL. Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. *AJR Am J Roentgenol* 2020;214:105-13.
14. Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marte JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, **Madan RA**, Schlom J, Gulley JL. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with human papillomavirus-associated malignancies. *J Immunother Cancer* 2020;8.
15. Schmidt KT, Peer CJ, Huitema ADR, Williams MD, Wroblewski S, Schellens JHM, **Madan RA**, Figg WD. Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. *J Pharm Biomed Anal* 2020;181:113073.
16. Schmidt KT, Huitema ADR, Dorlo TPC, Peer CJ, Cordes LM, Sciuto L, Wroblewski S, Pommier Y, **Madan RA**, Thomas A, Figg WD. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. *Cancer Chemother Pharmacol* 2020;86:475-86.
17. S UG, **Madan RA**, Aragon-Ching JB. The immunotherapy revolution in genitourinary malignancies. *Immunotherapy* 2020;12:819-31.
18. **Madan RA**, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. *Clin Genitourin Cancer* 2020;18:258-67 e1.
19. **Madan RA**, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *J Natl Cancer Inst* 2020;112:562-73.
20. Karzai F, **Madan RA**, Dahut WL. How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer? *Eur Urol* 2020;77:36-7.
21. Karzai F, **Madan RA**, Dahut WL. The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic. *Clin Cancer Res* 2020;26:4198-200.

22. Gatti-Mays ME, Redman JM, Donahue RN, Palena C, **Madan RA**, Karzai F, Bilusic M, Sater HA, Marte JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. *Oncologist* 2020;25:479-e899.
23. Del Rivero J, Donahue RN, Marte JL, Gramza AW, Bilusic M, Rauckhorst M, Cordes L, Merino MJ, Dahut WL, Schlom J, Gulley JL, **Madan RA**. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. *Front Endocrinol (Lausanne)* 2020;11:490.
24. Del Rivero J, Cordes LM, Klubo-Gwiedzinska J, **Madan RA**, Nieman LK, Gulley JL. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. *Oncologist* 2020;25:290-300.
25. Collins JM, Donahue RN, Tsai YT, Manu M, Palena C, Gatti-Mays ME, Marte JL, **Madan RA**, Karzai F, Heery CR, Strauss J, Abdul-Sater H, Cordes L, Schlom J, Gulley JL, Bilusic M. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. *Oncologist* 2020;25:560-e1006.
26. Chau V, **Madan RA**, Figg WD. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. *Cancer Biol Ther* 2020;21:884-7.
27. Bilusic M, Einstein DJ, Karzai FH, Dahut WL, Gulley JL, Aragon-Ching JB, **Madan RA**. The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. *Urol Clin North Am* 2020;47:457-67.
28. Aragon-Ching JB, **Madan RA**. Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. *Cancer* 2020;126:5210-2.
29. Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, **Madan RA**, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. *Ann Oncol* 2020;31:369-76.
30. Al Harthy M, Redman J, **Madan RA**. Novel immunotherapy combinations for genitourinary cancers. *Expert Opin Biol Ther* 2020;20:253-62.
31. Abdul Sater H, Marte JL, Donahue RN, Walter-Rodriguez B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M, Harmon SA, Turkbey IB, Choyke PL, Schlom J, Dahut WL, **Madan RA**, Pinto PA, Gulley JL. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. *J Immunother Cancer* 2020;8.
32. Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, **Madan RA**, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. *Oncologist* 2019;24:1259-69.
33. Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marte JL, **Madan RA**, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. *Clin Cancer Res* 2019;25:99-109.
34. Redman JM, Rhea LP, Cordes L, Owens H, **Madan RA**, Bilusic M, Gulley JL, Lee JM, Dahut WL, Karzai F. A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. *Clin Genitourin Cancer* 2019;17:e549-e52.
35. Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, **Madan RA**, Ballester LY, Pittaluga S, Donahue RN, Tsai YT, Lepone LM, Chin K, Ginty F, Sood A, Hewitt SM, Schlom J, Hassan R, Gulley JL. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. *J Immunother Cancer* 2019;7:269.
36. Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, **Madan R**, Figg WD. A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in

patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. *Cancer Chemother Pharmacol* 2019;84:759-70.

37. **Madan RA**, Gulley JL. Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment. *J Natl Cancer Inst* 2019;111:219-20.
38. Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, **Madan RA**, Choyke PL, Turkbey B, Dahut W, Pinto PA. mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. *Urol Oncol* 2019;37:352 e25- e30.
39. Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, **Madan RA**, Marte JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. *Clin Cancer Res* 2019;25:4933-44.
40. Del Rivero J, Edgerly M, Ward J, **Madan RA**, Balasubramaniam S, Fojo T, Gramza AW. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. *Oncologist* 2019;24:16-e4.
41. Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, **Madan RA**, Karzai F, Marte JL, Strauss J, Gatti-Mays ME, Schlom J, Gulley JL. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. *J Immunother Cancer* 2019;7:240.
42. Strauss J, Heery CR, Schlom J, **Madan RA**, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors. *Clin Cancer Res* 2018;24:1287-95.
43. Schmidt KT, **Madan RA**, Figg WD. Expanding the use of abiraterone in prostate cancer: Is earlier always better? *Cancer Biol Ther* 2018;19:97-100.
44. Redman JM, **Madan RA**. Spotlight on atezolizumab and its potential as an oncology agent. *Expert Rev Anticancer Ther* 2018;18:719-22.
45. Pezaro CJ, Marciscano AE, **Madan RA**. The Winds of Change: Emerging Therapeutics in Prostate Cancer. *Am Soc Clin Oncol Educ Book* 2018;38:382-90.
46. Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, **Madan RA**, Donahue RN, Chow HS. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. *Eur Urol Focus* 2018;4:636-8.
47. Marciscano AE, **Madan RA**. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. *Curr Treat Options Oncol* 2018;19:16.
48. **Madan RA**, Gulley JL. Pembrolizumab: patient selection or immune intensification? *Nat Rev Urol* 2018;15:593-4.
49. Karzai F, VanderWeele D, **Madan RA**, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marte J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. *J Immunother Cancer* 2018;6:141.
50. Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, **Madan RA**, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL. A comparison of prostate cancer bone metastases on (18)F-Sodium Fluoride and Prostate Specific Membrane Antigen ((18)F-PSMA) PET/CT: Discordant uptake in the same lesion. *Oncotarget* 2018;9:37676-88.



51. Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, **Madan RA**, Gulley JL, Mease RC, Jacobs PM, Pomper MG, Turkbey B, Choyke PL, Lindenberg ML. A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-Targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer. *J Nucl Med* 2018;59:1665-71.
52. Cordes LM, Gulley JL, **Madan RA**. Perspectives on the clinical development of immunotherapy in prostate cancer. *Asian J Androl* 2018;20:253-9.
53. Aragon-Ching JB, **Madan RA**. The path forward in prostate cancer therapeutics. *Asian J Androl* 2018;20:213-4.
54. Roman JW, Ojemuyiwa MA, Cordes LM, **Madan RA**, Sperling L. Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids. *JAAD Case Rep* 2017;3:322-5.
55. Redman JM, Gulley JL, **Madan RA**. Combining immunotherapies for the treatment of prostate cancer. *Urol Oncol* 2017;35:694-700.
56. **Madan RA**, Gulley JL. Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy. *Nat Rev Urol* 2017;14:455-6.
57. **Madan RA**, Gulley JL. Prostate cancer immunotherapy: the path forward. *Curr Opin Support Palliat Care* 2017;11:225-30.
58. Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marte J, Dahut W, Singh H, **Madan RA**, Fernando RI, Hamilton DH, Schlom J, Gulley JL. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. *Clin Cancer Res* 2017;23:6833-45.
59. Heery CR, O'Sullivan-Coyne G, **Madan RA**, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. *Lancet Oncol* 2017;18:587-98.
60. Gulley JL, **Madan RA**, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. *J Natl Cancer Inst* 2017;109.
61. Fakhrejehani F, **Madan RA**, Dahut WL. Management Options for Biochemically Recurrent Prostate Cancer. *Curr Treat Options Oncol* 2017;18:26.
62. Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, **Madan RA**, Heery CR, Gulley JL, Schlom J. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. *J Immunother Cancer* 2017;5:20.
63. Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, **Madan R**, Fojo T. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. *Oncologist* 2017;22:888-e84.
64. Bilusic M, **Madan RA**, Gulley JL. Immunotherapy of Prostate Cancer: Facts and Hopes. *Clin Cancer Res* 2017;23:6764-70.
65. Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, **Madan RA**, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. *Clin Genitourin Cancer* 2017;15:77-85.
66. Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, **Madan RA**, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. *Oncoimmunology* 2016;5:e1197459.

67. Wattenberg MM, Fong L, **Madan RA**, Gulley JL. Immunotherapy in genitourinary malignancies. *Curr Opin Urol* 2016;26:501-7.
68. Strauss J, **Madan RA**, Gulley JL. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. *Expert Opin Biol Ther* 2016;16:895-901.
69. Strauss J, **Madan RA**. Therapeutic vaccines for prostate cancer: recent advances and future directions. *Expert Rev Vaccines* 2016;15:907-14.
70. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, **Madan RA**, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. *J Immunother Cancer* 2016;4:92.
71. **Madan RA**, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Chen C, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. *BJU Int* 2016;118:590-7.
72. **Madan RA**, Gulley JL, Dahut WL. Radium-223 in prostate cancer: emitting the right signals. *Lancet Oncol* 2016;17:1186-7.
73. **Madan RA**, Gulley JL. Prospects for the future of prostate cancer vaccines. *Expert Rev Vaccines* 2016;15:271-4.
74. Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, **Madan RA**, Gulley JL, Schlom J. Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. *J Circ Biomark* 2016;5:5.
75. Karzai FH, **Madan RA**, Dahut WL. Metabolic syndrome in prostate cancer: impact on risk and outcomes. *Future Oncol* 2016;12:1947-55.
76. Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, **Madan RA**, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. *Oncotarget* 2016;7:37762-72.
77. Heery CR, **Madan RA**, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marte JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. *Oncotarget* 2016;7:69014-23.
78. Gulley JL, **Madan RA**. Developing immunotherapy strategies in the treatment of prostate cancer. *Asian J Urol* 2016;3:278-85.
79. Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, **Madan RA**, Heery CR, Gulley JL, Schlom J. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. *Cancer Immunol Res* 2016;4:755-65.
80. Cordes LM, Gulley JL, **Madan RA**. The evolving role of immunotherapy in prostate cancer. *Curr Opin Oncol* 2016;28:232-40.
81. Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, **Madan RA**, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. *J Nucl Med* 2016;57:886-92.
82. Strauss J, **Madan RA**, Figg WD. Evaluating immune responses after sipuleucel-T therapy. *Cancer Biol Ther* 2015;16:1119-21.

83. Strauss J, **Madan RA**. Integrating Immunotherapies in Prostate Cancer. *Curr Oncol Rep* 2015;17:45.
84. McNeel DG, Chen YH, Gulley JL, Dwyer AJ, **Madan RA**, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). *Hum Vaccin Immunother* 2015;11:2469-74.
85. **Madan RA**, Gulley JL. (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment. *J Natl Cancer Inst* 2015;107:347.
86. **Madan RA**, Gulley JL. Moving the goal posts in prostate cancer trials. *Lancet Oncol* 2015;16:247-9.
87. **Madan RA**, Dahut WL. Prostate cancer: Charting a course in metastatic castration-sensitive prostate cancer. *Nat Rev Urol* 2015;12:368-9.
88. **Madan R**, Dahut WL. Abiraterone's efficacy confirmed; time to aim higher. *Lancet Oncol* 2015;16:119-21.
89. Lu D, Graf RP, Harvey M, **Madan RA**, Heery C, Marte J, Beasley S, Tsang KY, Krupa R, Louw J, Wahl J, Bales N, Landers M, Marrinucci D, Schlom J, Gulley JL, Dittamore R. Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. *J Circ Biomark* 2015;4:4.
90. Karzai FH, **Madan RA**, Figg WD. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. *South Med J* 2015;108:224-8.
91. Karzai FH, Apolo AB, Cao L, **Madan RA**, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL. A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. *BJU Int* 2015;116:546-55.
92. Heery CR, Singh BH, Rauckhorst M, Marte JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, **Madan RA**, Schlom J, Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. *Cancer Immunol Res* 2015;3:1248-56.
93. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, **Madan RA**, McMahon S, Marte JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL. Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial. *JAMA Oncol* 2015;1:1087-95.
94. Gulley JL, Marte J, Heery CR, **Madan RA**, Steinberg SM, Leitman SF, Tsang KY, Schlom J. The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. *Cancer Immunol Immunother* 2015;64:1429-35.
95. Gabitzsch ES, Tsang KY, Palena C, David JM, Fantini M, Kwilas A, Rice AE, Latchman Y, Hodge JW, Gulley JL, **Madan RA**, Heery CR, Balint JP, Jr., Jones FR, Schlom J. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. *Oncotarget* 2015;6:31344-59.
96. Yavuz S, Apolo AB, Kummar S, del Rivero J, **Madan RA**, Shawker T, Reynolds J, Celi FS. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. *Thyroid* 2014;24:1223-31.
97. Surolia I, Gulley J, **Madan RA**. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. *Expert Opin Biol Ther* 2014;14:1769-81.
98. Sternberg CN, Petrylak DP, **Madan RA**, Parker C. Progress in the treatment of advanced prostate cancer. *Am Soc Clin Oncol Educ Book* 2014:117-31.
99. Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, **Madan RA**, Heery CR, Gulley JL. Therapeutic cancer vaccines. *Adv Cancer Res* 2014;121:67-124.

100. Ojemuyiwa MA, **Madan RA**, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. *Expert Opin Emerg Drugs* 2014;19:459-70.
101. O'Sullivan Coyne G, **Madan RA**, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. *J Clin Oncol* 2014;32:986-8.
102. **Madan RA**, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. *Oncoimmunology* 2014;3:e28611.
103. Jochems C, Tucker JA, Tsang KY, **Madan RA**, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. *Cancer Immunol Immunother* 2014;63:407-18.
104. Gulley JL, **Madan RA**, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. *Cancer Immunol Res* 2014;2:133-41.
105. Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, **Madan RA**, Gulley JL, Schlom J. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. *Int J Cancer* 2014;135:862-70.
106. Dahut WL, **Madan RA**. Real-world experience with abiraterone. *Lancet Oncol* 2014;15:1188-90.
107. Burotto M, Singh N, Heery CR, Gulley JL, **Madan RA**. Exploiting synergy: immune-based combinations in the treatment of prostate cancer. *Front Oncol* 2014;4:351.
108. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, **Madan RA**. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. *Cancer Immunol Immunother* 2014;63:225-34.
109. Singh N, **Madan RA**, Gulley JL. Ipilimumab in prostate cancer. *Expert Opin Biol Ther* 2013;13:303-13.
110. **Madan RA**, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. *Oncologist* 2013;18:821-2.
111. **Madan RA**, Shah AA, Dahut WL. Is it time to reevaluate definitive therapy in prostate cancer? *J Natl Cancer Inst* 2013;105:683-5.
112. **Madan RA**, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. *Cancer J* 2013;19:50-8.
113. **Madan RA**, Gulley JL. Prostate cancer: Intermediate efficacy end points to assess modern therapies. *Nat Rev Urol* 2013;10:686-7.
114. **Madan RA**, Arlen PM. Recent advances revolutionize treatment of metastatic prostate cancer. *Future Oncol* 2013;9:1133-44.
115. Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM, **Madan RA**, Gulley JL, Schlom J, Tsang KY. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. *Int J Cancer* 2013;133:373-82.
116. Huang J, Jochems C, Anderson AM, Talaie T, Jales A, **Madan RA**, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. *J Immunol* 2013;190:6250-8.
117. Gulley JL, **Madan RA**, Heery CR. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. *Am Soc Clin Oncol Educ Book* 2013.

118. Gulley JL, Heery CR, **Madan RA**, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. *Cancer Immunol Immunother* 2013;62:1521-31.
119. Figg WD, Chau CH, **Madan RA**, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. *Clin Genitourin Cancer* 2013;11:229-37.
120. Dahut WL, **Madan RA**, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. *BJU Int* 2013;111:1269-80.
121. Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, **Madan R**, Shore ND. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. *Eur Urol* 2012;61:639-47.
122. **Madan RA**, Schwaab T, Gulley JL. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. *J Natl Compr Canc Netw* 2012;10:1505-12.
123. **Madan RA**, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. *Lancet Oncol* 2012;13:501-8.
124. **Madan RA**, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. *Oncoimmunology* 2012;1:1167-8.
125. **Madan RA**, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. *Semin Oncol* 2012;39:296-304.
126. Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, **Madan RA**, Landgren O, Choyke PL. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. *J Nucl Med* 2012;53:1175-84.
127. Kim JW, **Madan RA**, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. *Clin Genitourin Cancer* 2012;10:43-6.
128. Kim JW, Bilusic M, Heery CJ, **Madan RA**. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. *Cancers (Basel)* 2012;4:1229-46.
129. Kamrava M, Kesarwala AH, **Madan RA**, Lita E, Kaushal A, Tsang KY, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. *Prostate Cancer Prostatic Dis* 2012;15:289-95.
130. Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, **Madan RA**, Gulley JL, Schlom J. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. *Blood* 2012;120:3030-8.
131. Bilusic M, **Madan RA**. Therapeutic cancer vaccines: the latest advancement in targeted therapy. *Am J Ther* 2012;19:e172-81.
132. Vergati M, Cereda V, **Madan RA**, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. *Cancer Immunol Immunother* 2011;60:197-206.
133. Stein WD, Gulley JL, Schlom J, **Madan RA**, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. *Clin Cancer Res* 2011;17:907-17.
134. Mohebtash M, Tsang KY, **Madan RA**, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL. A pilot study of

- MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. *Clin Cancer Res* 2011;17:7164-73.
135. **Madan RA**, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. *Clin Cancer Res* 2011;17:3892-902.
136. **Madan RA**, Gulley JL. Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. *Immunotherapy* 2011;3:27-31.
137. **Madan RA**, Gulley JL. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. *Expert Rev Vaccines* 2011;10:141-50.
138. **Madan RA**, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. *Expert Rev Vaccines* 2011;10:743-53.
139. Gulley JL, **Madan RA**, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. *Expert Opin Biol Ther* 2011;11:1409-18.
140. Gulley JL, **Madan RA**, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. *Curr Oncol* 2011;18:e150-7.
141. Bilusic M, Heery C, **Madan RA**. Immunotherapy in prostate cancer: emerging strategies against a formidable foe. *Vaccine* 2011;29:6485-97.
142. Zhu W, Zhu DS, **Madan RA**, Gulley JL, Figg WD, Dahut WL. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. *Am J Ther* 2010;17:176-81.
143. Rotow J, Gameiro SR, **Madan RA**, Gulley JL, Schlom J, Hodge JW. Vaccines as monotherapy and in combination therapy for prostate cancer. *Clin Transl Sci* 2010;3:116-22.
144. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, **Madan RA**, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. *J Clin Oncol* 2010;28:2070-6.
145. **Madan RA**, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. *Expert Opin Biol Ther* 2010;10:19-28.
146. **Madan RA**, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. *Oncologist* 2010;15:969-75.
147. **Madan RA**, Gulley JL. The current and emerging role of immunotherapy in prostate cancer. *Clin Genitourin Cancer* 2010;8:10-6.
148. Gulley JL, Arlen PM, **Madan RA**, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. *Cancer Immunol Immunother* 2010;59:663-74.
149. Dahut WL, **Madan RA**. Revisiting the ultimate target of treatment for prostate cancer. *Lancet* 2010;375:1409-10.
150. Aragon-Ching JB, **Madan RA**, Dahut WL. Angiogenesis inhibition in prostate cancer: current uses and future promises. *J Oncol* 2010;2010:361836.
151. Mohebtash M, Gulley JL, **Madan RA**, Ferrara T, Arlen PM. Cancer vaccines: current directions and perspectives in prostate cancer. *Curr Opin Mol Ther* 2009;11:31-6.

152. **Madan RA**, Dahut WL. Angiogenesis inhibition in the treatment of prostate cancer. *Anticancer Agents Med Chem* 2009;9:1070-8.
153. **Madan RA**, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostavac-VF: a vector-based vaccine targeting PSA in prostate cancer. *Expert Opin Investig Drugs* 2009;18:1001-11.
154. Kamrava M, Tsang KY, **Madan RA**, Kaushal A, Coleman CN, Gulley J. Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer. *Clin Dev Immunol* 2009;2009:363914.
155. Arlen PM, Mohebtash M, **Madan RA**, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. *Future Oncol* 2009;5:187-96.
156. Mohebtash M, **Madan RA**, Gulley JL, Arlen PM. Therapeutic prostate cancer vaccines: a review of the latest developments. *Curr Opin Investig Drugs* 2008;9:1296-301.
157. **Madan RA**, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. *Clin Cancer Res* 2008;14:4526-31.
158. **Madan RA**, Xia Q, Chang VT, Oriscello RG, Kasimis B. A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. *Expert Opin Pharmacother* 2007;8:1425-31.
159. **Madan RA**, Lieberman R, Gulley JL, Dahut W, Arlen PM. Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature. *Am J Ther* 2007;14:310-3.
160. **Madan RA**, Chang VT, Dever LL. An uncommon presentation of HIV-related lymphoma. *AIDS Patient Care STDS* 2007;21:443-6.
161. **Madan RA**, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. *Expert Opin Biol Ther* 2007;7:543-54.
162. Gulley JL, **Madan RA**, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. *Vaccine* 2007;25 Suppl 2:B89-96.
163. Arlen PM, **Madan RA**, Hodge JW, Schlom J, Gulley JL. Combining Vaccines with Conventional Therapies for Cancer. *Update Cancer Ther* 2007;2:33-9.
164. Arlen PM, Gulley JL, **Madan RA**, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. *Crit Rev Immunol* 2007;27:451-62.
165. **Madan RA**, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. *Expert Rev Vaccines* 2006;5:199-209.
166. **Madan RA**, Arlen PM. Abiraterone. *Cougar Biotechnology. IDrugs* 2006;9:49-55.
167. **Madan RA**, Chang VT, Yook C, Baddoura FK, Srinivas S, Kasimis B. Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature. *Leukemia* 2004;18:1433-5.
168. Goldberg SL, **Madan RA**, Rowley SD, Pecora AL, Hsu JW, Tantravahi R. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. *Blood* 2003;101:781.

**Book Chapters (selected)**

1. Bander NH, van den Eertwegh A, Fong, LE, **Madan RA** McNeel, D, O'sullivan,G, Nguyen D, Santegoets S, Stam A, Suurs F, van de Ven R, Zambran. "Vaccines, Immunotherapies and Gene-Based

Therapies” In: *Medical Treatment of Urologic Malignancies*. Stief C., Fizazi K, Evans CP, Eds. Lisbon: ICUD-EAU, 2015.

2. **Madan RA**, Dahut WL, “Prostate Cancer.” In: *Bethesda Handbook of Clinical Oncology*, 4th ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2014:191-207.
3. Adesunloye BA, **Madan RA**, “Prostate Cancer.” In: *Bethesda Handbook of Clinical Oncology*, 4th ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2014:218-232.
4. **Madan RA**, Ferrara TA, Gulley JL, “Therapeutic Cancer Vaccines: An Emerging Approach to Cancer” In: *Treatment Handbook of Anticancer Pharmacokinetics and Pharmacodynamics*, Springer Publications, *in press*.
5. Heery CR, Bilusic M, **Madan RA**. “Emerging treatment strategies for metastatic prostate cancer: the next step forward.” In: *Emerging Cancer Therapeutics*. Gulley J, Abraham J, eds. New York; Demos Medical Publishing; 2011:597-612.
6. Schlom J, **Madan RA**, Bilusic M, Heery CR, Hodge JW, Gulley JL. “Immune targeting of prostate cancer.” In: *ASCO 2011 Genitourinary Cancers Symposium Education Book*.
7. **Madan RA**, Gulley JL, Celestin J, Arlen PA, Schlom J. “Cancer immunology, immunotherapeutics and vaccine approaches.” In: *Drug Management of Prostate Cancer*. Figg W, Chau C, Small EJ, eds. New York: Springer; 2010:305-19.
8. **Madan RA**, Kramer BS. “Testicular carcinoma.” In: *Bethesda Handbook of Clinical Oncology*, 3<sup>rd</sup> ed. Abraham J, Gulley JL, Allegra CJ, eds. Philadelphia: Lippincott, Williams & Wilkins; 2010:210-230.
9. Aragon-Ching J, **Madan RA**, Gulley JL. “The clinical utility of bevacizumab.” In: *Angiogenesis: An Integrative Approach from Science to Medicine*. Figg W, Folkman J, eds. New York: Springer Science+Business Media; 2008:375-86.

### Abstracts

*Over 200 Abstracts at National and International Meetings*

### Peer Reviewer Activity

*Asian Journal of Andrology*  
*Cancer*  
*Cancer Immunology, Immunotherapy*  
*Cancer Immunology Research*  
*Cancer Investigation*  
*Cancer Research*  
*Cellular and Molecular Life Sciences*  
*Clinical Investigation*  
*Clinical Cancer Research*  
*Clinical Genitourinary Cancer*  
*Expert Opinion on Biological Therapy*  
*Expert Opinion on Pharmacotherapy*  
*Expert Review of Clinical Pharmacology*  
*Expert Review of Vaccines*  
*European Urology*  
*European Urology Oncology*  
*Genitourinary Malignancies*  
*Hospital Medicine*  
*International Journal of Cancer*  
*Immunotherapy*  
*Journal of Clinical Oncology*



*JCO Clinical Practice*  
*Journal of Immunotherapy for Cancer*  
*Journal of the American Medical Association*  
*The Lancet*  
*Lancet Oncology*  
*Molecular Cancer Therapeutics*  
*Nature*  
*Nature Oncology*  
*Nature Reviews Urology*  
*Oncoimmunology*  
*Oncotarget*  
*Scientific Reports*  
*Technology in Cancer Research and Treatment*  
*Therapeutic Advances in Medical Oncology*  
*Urologic Oncology: Seminars and Original Investigations*